USFDA approves neurological drug from Zydus
With 160 ANDAs pending by the Zydus group, this is the 100th approval on the listZydus Cadila has received the green signal to market the Pyridostigmine Bromide Tablets USP, 60 mg. The approval comes from the US drug regulator, USFDA and is a milestone achievement for the company, as it strikes one more new drug approval from the total application of 260 filed till date.This lucky number...
Login or Register to read the full article
With 160 ANDAs pending by the Zydus group, this is the 100th approval on the list
Zydus Cadila has received the green signal to market the Pyridostigmine Bromide Tablets USP, 60 mg. The approval comes from the US drug regulator, USFDA and is a milestone achievement for the company, as it strikes one more new drug approval from the total application of 260 filed till date.
This lucky number of 100th drug application (from over 260 ANDAs since the commencement of the filing process in FY 2003-04) approval, is estimated to generate a whopping sale of $27.9 million as per IMS. The drug in action is used for treatment of various neurological disorders
Zydus Cadila has received the green signal to market the Pyridostigmine Bromide Tablets USP, 60 mg. The approval comes from the US drug regulator, USFDA and is a milestone achievement for the company, as it strikes one more new drug approval from the total application of 260 filed till date.
This lucky number of 100th drug application (from over 260 ANDAs since the commencement of the filing process in FY 2003-04) approval, is estimated to generate a whopping sale of $27.9 million as per IMS. The drug in action is used for treatment of various neurological disorders
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd